Each year in the United States, nearly 13,000 women develop cervical cancer and 4000 die
from the disease. 1 However, most cases can be prevented with vaccination and screening …

Methods From October 2013 to February 2015, the ACIP HPV Vaccine Work Group
reviewed clinical trial data assessing the efficacy, immunogenicity, and safety of 9vHPV …

In 2014, the Food and Drug Administration approved a new human papillomavirus 9-valent
vaccine (9vHPV), targeting nine HPV types: HPV types 6, 11, 16, and 18, which are also …

Cancer is the leading cause of death among Hispanics/Latinos, who represent the largest
racial/ethnic minority group in the United States, accounting for 17.4%(55.4 million/318 …

Background: The impact of human papillomavirus (HPV) vaccination has been observed in
the United States through declining cervical precancer incidence in young women. To …

HPV35 has been found in only∼ 2% of invasive cervical cancers (ICC) worldwide but up to
10% in Sub‐Saharan Africa, warranting further investigation and consideration of impact on …

Background: Randomized clinical trials have shown the 9-valent human papillomavirus
(HPV) vaccine to be highly effective against types 31/33/45/52/58 compared with the 4 …

Background Racial and ethnic variations in attribution of cervical precancer and cancer to
human papillomavirus (HPV) types may result in different HPV vaccine protection, screening …

HPV infection results in changes in host gene methylation which, in turn, are thought to
contribute to the neoplastic progression of HPV-associated cancers. The objective of this …

Cervical cancer causes significant morbidity and mortality worldwide. Most cervical cancers
are associated with oncogenic human papillomavirus (HPV), and vaccination with any of 3 …